HIMSS: Advanced EMRs more likely to produce positive results

Hospitals with advanced EMR have noticed promising results in multiple areas since implementation, according to research conducted by HIMSS Analytics, the research arm of the Healthcare Information and Management Systems Society (HIMSS), and the Advisory Board, a research and consulting firm headquartered in Washington, D.C.

In late 2011, researchers sent email surveys to CIOs at approximately 180 hospitals that have achieved Stage 6 or Stage 7 status on the HIMSS Electronic Medical Record Adoption Model (EMRAM) scale. They received responses from 18 percent of the organizations queried, with six respondents representing Stage 7 hospitals and 27 representing Stage 6 hospitals. Survey results were published in a February white paper.

Out of the 33 total respondents, all reported having met and documented at least one core measure benefit and one safety measure benefit, with 79 percent reporting that they achieved multiple benefits. Reduction in the number of adverse drug events was the most commonly reported, with 73 percent claiming the achievement.

Researchers determined that hospitals targeting specific areas were more likely to achieve improvements in those areas than others, noting that 77 percent of the hospitals that targeted adverse drug event reductions achieved them.

Additionally, the majority of respondents reported benefits including reduction in order turnaround time, improved drug order to administration times, decreased cost of paper forms, improved charge capture, decreased transcription costs, reduction in duplicate lab testing, reduction in antibiotic start times and improved documentation quality.

Based on the results of the survey, researchers determined that hospitals with advanced EMRs according to the EMRAM scale were more able and likely to realize substantial benefits.

The white paper is available in its entirety here.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup